1

Welcome to ATCGbio Life Technology Inc.

Advancing Life Sciences Technology

shRNA-Mmp3 (matrix metallopeptidase 3) Lentivirus Plasmid (SH1001-09m)

Availability: In stock

USD$360.00
OR

Quick Overview

ATCGbio Life Technology Inc. provides the function-validated shRNA-Mmp3 (matrix metallopeptidase 3) lentivirus plasmid. 
The plasmids product contains 2-tubes:
1. Negative-control shRNA lentivirus plasmid  20 µl (~50 ng/µl)
2. shRNA-Mmp3 (matrix metallopeptidase 3) lentivirus plasmid   20 µl (~50 ng/µl)

shRNA-Mmp3 (matrix metallopeptidase 3) Lentivirus Plasmid (SH1001-09m)

Details

                           Produtct Name:         shRNA-Mmp3 Lentivirus Plasmid
 
        Official Gene Symbol:
                   Mmp3
 
        Gene ID:         17392  
        Official Full Name:         matrix metallopeptidase 3  
        Also Known As:         SLN1; Str1; SLN-1; STR-1; Stmy1  
        Target Species:         Mus musculus  
        Product Validation:         shRNA Function validated  
        Technique Information:         Instruction PDF| Web Page|MSDS  
        Product Size:         20µl (~50ng/µl), store at 4°C  
        Product Category:         RNAi, Cat#SH1001-09m  
        Price (USD):         $350.00  
                     

Lentivirus plasmids will be shipped in 0.5 ml tube, and users are free to amplify. Upon receiving the tubes, keep it at 4 °C till amplification.

Expression of MMP3 is primarily regulated at the level of transcription, where the promoter of the gene responds to various stimuli, including growth factors, cytokines, tumor promoters, and oncogene products. Recently, the MMP3 gene was shown to be downregulated in individuals with cleft lip and palate when compared to controls,reinforcing the nature of cleft lip/palate as a condition resulting from insufficient or defective embryonic tissue remodeling.

Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix and during tissue remodeling in normal physiological processes, such as embryonic development and reproduction, as well as in disease processes, such as arthritis, and tumour metastasis. Most MMPs are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. The MMP-3 enzyme degrades collagen types II, III, IV, IX, and X, proteoglycans, fibronectin, laminin, and elastin. In addition, MMP-3 can also activate other MMPs such as MMP-1, MMP-7, and MMP-9, rendering MMP-3 crucial in connective tissue remodeling. The enzyme is thought to be involved in wound repair, progression of atherosclerosis, and tumor initiation.

The following figure is the results of experiments to prove our shRNA performance

(One shRNA sequence was selected for one target in each design)

  
         shRNA-lentivirus-performance                   Non-target   Gene-specific
               shRNA           shRNA
• shRNA Lentivirus were created to target 10 transcription factors expressed in HepG2 cells.
• 64 hrs after infection without antibiotic selection, the target gene mRNAs were down to 28.8% in average of 10 shRNA target (p<0.0001 by paired t-test). 9 out of 10 design shRNA were able to suppress more than 70%, and only one out of 10 shRNA suppressed more modestly about 60%.
• Suppression will be greater, when the cells would be cultured longer time with antibiotics selection.
      

Ten transcription factors expressed in HepG2 cells were selected for this experiment. The lentivirus plasmids expressing shRNA were made for each target gene using our propriety design scheme (One shRNA sequence was selected for one target in each design). Lentivirus was created in 12-well plates using our Lentivirus Production kit, which produces a high titer stable lentivirus solution in 48hrs. HepG2 cells were grown in 96-well palate and infected with each virus including negative control shRNA by adding 50µl crude virus solution into HepG2 cells cultured with100µl culture medium for overnight(16hrs.). The cells were incubated further 48hrs., and harvested for Direct RT real-time PCR.  As shown in the right figure, 64 hrs. after infection, target gene mRNAs were down to 28.8% in average of 10 shRNA target. 9 out of 10 design shRNA were able to suppress more than 70%, and only one out of 10 shRNA suppressed more modestly about 60%.

References 

 1. Y. Ido, et al., PLoS ONE, 2012 Apr 07( 4): e35092
 2. Lan F, et al., J Biol Chem. 2008 Oct 10;283(41):27628-35.

Related Products

Lentivirus Production kit

Lentivirus Plasmids

Custom-made shRNA Lentivirus Plasmids 

RT-Real Time PCR Primers

FAQs

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.